Medical Presentations & Publications

 

PIXANTRONE

Date

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions in solid tumor lines

October 2013

The European Hematology Association 18th Congress (EHA): Pixantrone monotherapy in histologically confirmed, relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial

June 2013

The Lancet - Oncology: Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial

May 2012

American Society of Hematology (ASH): CPOP-R Versus CHOP-R as First-line Therapy for Diffuse Large B-cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-label, Multicenter Study

December 2011

American Society of Hematology (ASH) Annual Meeting and Exposition: Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): End of Study Results

December 2010

American Society of Hematology (ASH) 51st Annual Meeting and Exposition: Phase III trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma (EXTEND): Results from the treatment and follow-up periods

December 2009

Lymphoma & Myeloma 2009: Pixantrone: an overview of phase II and phase III studies in non-Hodgkin's lymphoma

October 2009

Pan Pacific Lymphoma Conference 2009: Overview of pixantrone dimaleate activity in NHL

June 2009

American Society of Clinical Oncology (ASCO) Annual Meeting: Randomized phase III trial of pixantrone versus other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive NHL

May 2009

American Society of Clinical Oncology (ASCO) Annual Meeting: Pixantrone significantly increases complete remissions, overall response rates, frequency of durable remissions and progression-free survival in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma (press release)

May 2009

American Society of Clinical Oncology (ASCO) Annual Meeting: Pixantrone produces high rates of complete and partial remissions even among aggressive NHL patients with extensive prior doxorubicin treatment or prior rituximab treatment (press release)

May 2009

2007 American Society of Hematology (ASH) Annual Meeting and Exposition: CHOP-R compared to CPOP-R in first-line therapy of diffuse large B cell lymphoma: an interim analysis

December 2007

American Society of Hematology (ASH) 48th Annual Meeting: Phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone (CPOP) in patients with relapsed aggressive non-Hodgkin's lymphoma

December 2006

American Society of Hematology (ASH) 48th Annual Meeting: Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma

December 2006

OPAXIO

Date

American Society of Clinical Oncology (ASCO) Annual Meeting: Paclitaxel Poliglumex (PPX), Temozolamide (TMZ) and Radiation (RT) for Newly Diagnosed High-Grade Gliomas: A Brown University Oncology Group (BrUOG) Phase II Study

June 2011

Society for Neuro-Oncology (SNO) Scientific Meeting: Paclitaxel Poliglumex (PPX), Temozolamide (TMZ), and Radiation (RT) for Newly Diagnosed High-Grade Gliomas: A Brown University Oncology Group (BrUOG) Phase II Study

November 2010

American Society of Clinical Oncology (ASCO) Annual Meeting: Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer

June 2010

International Society of Gastrointestinal Oncology (ISGIO) 2009 Gastrointestinal Oncology Conference: Neoadjuvant paclitaxel poliglumex (OPAXIO), cisplatin and radiation for esophageal cancer: a preliminary analysis of a phase II trial

October 2009

American Society of Clinical Oncology (ASCO) Annual Meeting: Paclitaxel poliglumex (OPAXIO™) added to cisplatin and radiation produces 45% pathologic complete remissions in patients With esophageal cancer (press release)

May 2009

You are now leaving website and entering the website.

If you would like to continue, click Continue.

CancelContinue